News

The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…

Asymptomatic damage to spinal nerves occurs even in clinically stable cases of multiple sclerosis (MS) and carries an increased risk for further lesions, a recent study suggests. Although a firm link between the asymptomatic loss of myelin in the spine and worsening disability remains to be found, this work…

Women with multiple sclerosis (MS) are not at a higher risk than those without the disease of having pregnancy complications, such as gestational diabetes, requiring an emergency cesarean section (c-section), or having a preterm or stillbirth delivery, according to the results of a new study. Yet, the study’s findings…

An estrogen-based therapy, called indazole chloride (IndCl), was shown to protect against optic nerve damage in a mouse model of multiple sclerosis (MS), a study reported. IndCl may help to improve vision in people with the disease, but…

Multiple Sclerosis Society of Canada have given CA$400,000 (about $312,500) to support a pilot clinical trial investigating the potential of metformin, a common diabetes therapy, to treat children and young adults with multiple sclerosis (MS). The Phase 1/2 feasibility trial (NCT04121468) is recruiting up to 30…

Telemedicine is a feasible and effective method of remote care for multiple sclerosis (MS) patients during the COVID-19 pandemic, an Italian study suggests. The study, “Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective,” was published in the journal Neurology International. The…

An online auction event supporting the National Multiple Sclerosis Society  is is running through Feb. 13 on Facebook. Organized by The Dyeing Arts group, the fundraising auction features tie dye and handcraft art from several online communities. The event arose from a partnership between Lighthouse Outdoor Products…

A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of multiple sclerosis (MS). The findings were published in the Journal of Neuroinflammation, in the study “Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of…

A $2.5 million donation from the Simon Family Trust is supporting the creation of a new center of expertise to help in the development of new therapies for multiple sclerosis (MS) and other neurological diseases. The new center is being launched by researchers from Gladstone Institutes and the…

The recently launched BRAINTEASER project focuses on the use of artificial intelligence (AI) technology to improve the care of patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). An initiative of a European consortium, BRAINTEASER could benefit patients, caregivers, and clinicians by enhancing the ability to predict,…

The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s…

Teams of scientists at the University of Toronto are sharing a nearly CA$21 million (about $16.36 million) award into research that might lead to self-repair treatments for multiple sclerosis (MS) and other neurological disorders, the university announced in a press release. Eleven teams at the university and its…

A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…

Long-term treatment with Tecfidera (dimethyl fumarate) safely and effectively reduces the frequency of relapses in children with relapsing-remitting multiple sclerosis (RRMS), according to 2.5 years of data from the FOCUS Phase 2 trial and its extension study. These findings are consistent with those previously reported for adult patients, supporting…

Rituximab shows long-term benefits, even among people with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) who stopped its use or reduced their dose, a study reported. Researchers found little evidence of disease reactivation among patients who discontinued the medication, and an adequate inflammatory disease suppression…

Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and functional abilities with multiple sclerosis (MS), as well as their utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels…

A newly identified subset of astrocytes — cells long thought to be responsible for simply providing nutrition and support to neurons — can prevent brain inflammation by promoting the destruction of pro-inflammatory immune T-cells, scientists report. Their work also found that the anti-inflammatory activity of this astrocyte subpopulation is dependent on…

Age is a main driver of disability in multiple sclerosis (MS) and has a key influence on patients’ therapeutic responses to Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), a study showed. Given those findings, age should be considered in the risk/benefit assessment that’s used in the decision-making process for…

Multiple sclerosis (MS)-associated inflammation in the cerebral cortex — the outermost layer of the brain that is involved in cognitive function — prompts the destruction of neural connections by specific immune cells, according to a study in a mouse model of MS. These immune cells targeted dendritic spines (nerve…

Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring neurodegenerative diseases. The technology is now being tested in people with multiple sclerosis (MS). Money raised by the Montreal-based startup came through a series A financing round led by Morningside Ventures.

People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen with ibudilast treatment in the SPRINT‐MS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…

A stem cell transplant can prevent disability progression and maintain disease remission over long periods of time in most patients with relapsing forms of multiple sclerosis (MS) who failed to respond adequately to disease-modifying therapies (DMTs), a study reports. The study, “Long-Term Clinical Outcomes of Hematopoietic…

The National Institute for Health and Care Excellence (NICE) does not recommend Zeposia (ozanimod) be available at low or no cost through the National Health Service (NHS) to treat adults with active relapsing-remitting multiple sclerosis (RRMS) living in England and Wales. In a recent draft recommendation, NICE stated that …

The upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum will focus on the spectrums of multiple sclerosis (MS), related inflammation, disease severity, and the latest findings in the field. According to an ACTRIMS press release, about 1,000 researchers and clinicians are expected to…

People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…

Oleic acid, a type of fatty acid, is important for the function of immune cells that are dysregulated in multiple sclerosis (MS), an early study shows. A diet rich in oleic acid may potentially be beneficial for these patients, although researchers emphasized the need for more studies. The study,…

Researchers from the Kessler Foundation will launch a new study investigating the effects of Tysabri (natalizumab) on cognitive fatigue — the type of fatigue that happens after strong mental concentration, such as in problem-solving — in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue, which is very…

A new primate model uncovered by researchers can help scientists understand the immune and inflammatory processes underlying the development of multiple sclerosis (MS) in humans, a study reports. It was already known that Japanese macaques — also called snow monkeys — can spontaneously develop encephalomyelitis (JME), a disorder that…

Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…

Changes in the amount of grey matter in specific regions of the brain appear to occur early in relapsing multiple sclerosis (MS), while structural changes in white matter happen late in disease progression. These were among the findings of a recent study that tracked the sequence of events in…